Journal
JOURNAL OF CONTROLLED RELEASE
Volume 342, Issue -, Pages 170-188Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2021.11.023
Keywords
Coronavirus disease-19; Inhalation therapy; Lung delivery; Pulmonary surfactant; Nanomedicine; Small-interfering RNA; Antiviral drugs; Severe acute respiratory syndrome coronavirus-2
Funding
- Research Foundation-Flanders, Belgium (FWO) [1S56121N]
- Ghent University Special Research Fund [BOF12-GOA-014, BOF19GOA-008]
- European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme [101002571]
- European Research Council (ERC) [101002571] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
The COVID-19 pandemic has had a significant impact globally, and while vaccination campaigns have proven effective, there is still a need to develop therapeutics specifically targeting COVID-19. This article highlights the potential of pulmonary surfactant (PS) in treating COVID-19 and its role in enhancing drug delivery.
The COVID-19 pandemic has wielded an enormous pressure on global health care systems, economics and politics. Ongoing vaccination campaigns effectively attenuate viral spreading, leading to a reduction of infected individuals, hospitalizations and mortality. Nevertheless, the development of safe and effective vaccines as well as their global deployment is time-consuming and challenging. In addition, such preventive measures have no effect on already infected individuals and can show reduced efficacy against SARS-CoV-2 variants that escape vaccine-induced host immune responses. Therefore, it is crucial to continue the development of specific COVID19 targeting therapeutics, including small molecular drugs, antibodies and nucleic acids. However, despite clear advantages of local drug delivery to the lung, inhalation therapy of such antivirals remains difficult. This review aims to highlight the potential of pulmonary surfactant (PS) in the treatment of COVID-19. Since SARS-CoV-2 infection can progress to COVID-19-related acute respiratory distress syndrome (CARDS), which is associated with PS deficiency and inflammation, replacement therapy with exogenous surfactant can be considered to counter lung dysfunction. In addition, due to its surface-active properties and membrane-interacting potential, PS can be repurposed to enhance drug spreading along the respiratory epithelium and to promote intracellular drug delivery. By merging these beneficial features, PS can be regarded as a versatile biomaterial to combat respiratory infections, in particular COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available